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Abstract
Introduction Cell-based therapies for regeneration of the
degenerated intervertebral disc (IVD) are an alternative to
current surgical intervention. Mesenchymal stem cells
(MSCs), in combination with a scaffold, might be ideal
candidates for regenerating nucleus pulposus (NP), the
pressure-distributing part of the IVD. While the use of
growth factors for MSCs differentiation currently receives
major attention, in this study we compare the performance
of sponge-like matrixes in supporting cell differentiation
into NP-like cells.
Materials and methods Four types matrixes approved as
medical devices for other applications were tested as
scaffolds for MSCs: two made of equine or porcine col-
lagen, one of gelatin and one of chitosan. Bone marrow-
derived human MSCs were seeded in these scaffolds or
embedded in alginate, as a three-dimensional control. After
five weeks in culture, NP-like differentiation of the cell-
scaffold constructs was analyzed by qRT-PCR, histology,
total DNA quantification, proteoglycan accumulation and
immunohistochemistry.
Results MSCs in collagen matrixes and gelatin produced
more mRNA and proteins of the chondrogenic markers
collagen type I, collagen type II (COL2) and aggrecan
(ACAN), when compared with cells embedded in alginate
or chitosan. Proteoglycan accumulation and cell survival
were also higher in collagen and gelatin matrixes. Gene
expression results were also confirmed by histological and
immunohistochemical staining. In contrast to alginate
control, the gene expression of the undesired bone marker
osteopontin was lower in all tested groups. In porcine
collagen supports, MSC expression ratio between COL2/
ACAN closely resembled the expression of nucleus pul-
posus cells, but gene expression of recently described NP
markers keratin19, PAX1 and FOXF1 was lower.
Conclusions Collagen supports provide a readily avail-
able, medically approved and effective scaffold for chon-
drogenic differentiation in vitro, but the phenotype of
differentiated MSCs is not yet completely equivalent to
that of NP cells.
Keywords Mesenchymal stem cells 
Chondrogenesis  Intervertebral disc 
Nucleus pulposus and three-dimensional cultures
Introduction
Regenerative medicine is a rapidly expanding field and
some potential treatments are already in clinical trial
stages, but still there are no available cures for interverte-
bral disc (IVD) degeneration. IVDs are considered as the
major ‘‘joints’’ of the spine and structurally they comprise
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of a gelatinous nucleus pulposus (NP) in the center, sur-
rounded by the collagen-rich annulus fibrosus (AF), and
they are connected on the upper and lower faces to the
vertebral body by cartilage the end-plates [1]. The main
components of the NP are an amorphous mix of proteo-
glycans, in particular aggrecan (ACAN), which by
absorbing water provide stiffness, compression resistance
and viscoelasticity, and collagen type II (COL2), which is
responsible for NP tensile strength [2]. This particular
matrix composition is qualitatively very similar to that of
the articular cartilage tissue, but it differs in the ratio
between proteoglycans and COL2; in cartilage it is 2:1,
whereas in the NP is 27:1 [3]. While multifactoral causes
for disc degeneration are proposed, such as genetics
(polymorphisms in the genes of SOX9 and Collagen type
IX [4]), age, lifestyle and extended mechanical loads on the
spine column [5], there is no consensus on what leads to
disc degeneration, which is characterized by decreased
extracellular matrix synthesis and cell death. Therefore,
cell-based therapies should have a potential, in terms of
recovery and healing of degenerated IVDs. Unlike gene
and molecular therapies, which have problems such as the
risks associated with viral gene transfer and growth factor
production issues (intellectual property ownership and
heavy clinical regulatory requirements) [6], autologous
cell-based therapies have the advantages of improved
safety and easier regulatory approval. Cell therapies have
been tested in animal models with some success for
degenerative disc disease [7], and some human clinical
trials show an increase in the height of the degenerated disc
and a reduction of pain in patients treated with disc-
chondrocyte cells [8]. IVD tissue engineering with cells
derived from the same tissue is characterized by some
important limitations, such as the low cell availability in
the degenerated tissue [9], and the great risk of damaging
an intact IVD if cells were to be explanted from a healthy
disc. Considering these problems, a better strategy to repair
a degenerated disc might be to search for a different, more
abundant cell type. The principal candidates for such
therapies are the mesenchymal stem cells (MSCs), which
are present in a number of tissues and can be extracted
from bone marrow, adipose tissue, synovial membrane and
umbilical cord tissue [10]. MSCs have a high proliferative
capacity [11] and have the ability to differentiate into
several cell types [12], including adipocytes [13], osteo-
cytes [14] and chondrocytes [15], although their differen-
tiation potential diminishes with passages in vitro [16]. As
NP cells have a similar morphology and gene expression
profile to articular chondrocytes, one can presume that
MSCs might be able to differentiate into NP cells. In the
disc, though, MSCs will face the challenges of a difficult
environment, being the largest avascular organ of the
human body, under constant load and hypoxic conditions
[1]. In the case of implantation of a substantial number of
stem cells, such conditions can lead to cell death rather
than cell differentiation and matrix production. Addition-
ally, after the removal of degenerated disc tissue, the
implanted cells may need too much time to differentiate
and generate new disc tissue and a more probable scenario
might be that undesired scar tissue is formed instead [17].
To address these problems, the goal is to improve the
viability of the cells and to accelerate the process of matrix
production, which could be achieved by pre-differentiation
of MSCs with the use of three-dimensional (3D) extracel-
lular scaffolds. The use of scaffolds is a key step in the
culturing of MSC for our understanding of cell fate and cell
based therapies. Scaffolds facilitate cellular attachment,
provide mechanical advantages for cell growth and an
implantable scaffold should be suited to help infiltration,
proliferation, and differentiation of MSC, thus mimicking
the in vivo environment. A good scaffold should aid the
introduction of chemical stimuli by appropriate composi-
tion of the matrix, which can immobilize growth factors
and keep them at a higher local concentration than in the
liquid phase of the culture. To induce MSC chondrogenesis
growth factors such as transforming growth factor (TGF)-
b1, 2 or 3 [18], bone morphogenetic protein-2 [19], -4 [20],
-7 [21] or -14 (GDF-5) [22], have been described to
facilitate MSCs differentiation, however the aim of this
project was to focus on the differences caused by variety of
matrixes. In particular, many studies already described
culture of MSCs embedded in several types of scaffolds,
such as agarose gels [23], alginate beads [24–26], synthetic
polymers [27, 28] and other biomaterials [29–32]. These
studies provide clear evidence that there is a need of a cell
support for enhancing cell–cell and cell–matrix interactions
and creating a 3D environment. In vitro differentiation of
MSCs would require materials that were non-immuno-
genic, biodegradable and can withstand the mechanically
loaded environment into the IVD. These scaffolds would
have to degrade slowly (or not at all) to allow the seeded
cells to differentiate and produce new matrix. The scaffolds
tested in this work are sponge-like medical devices, of
different composition, stiffness and porosity, which are
normally used in surgical intervention as a support in
wound management, as a haemostat or in wound healing.
We hypothesized that approved medical devices can be
used as scaffolds for chondrogenic differentiation of
MSCs in 3D cultures and analyzed in vitro differentiation
of bone marrow-derived MSCs towards NP-like pheno-
type in four such matrixes, made of equine and porcine
collagen, gelatin and chitosan. We investigated the grade
of MSCs differentiation into a NP-like phenotype ana-
lyzing the expression and production of extracellular
matrix proteins, and we compared the results with NP
cells and fragments.
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Materials and methods
Scanning electron microscopy and stiffness
measurements of matrixes
For electron microscopy, a Philips XL 30 FEG ESEM was
used. Secondary electron images were recorded using an
acceleration voltage of 10 kV.
For the determination of the matrix stiffness, cylindrical
specimens (6 mm diameter) were prepared with a biopsy
punch and mounted between two parallel metal platens.
Specimens were compressed in a ramp-and-hold sequence
and the reaction force recorded by a load cell (10 N, ELPF,
Measurement Specialties, Hampton, VA, USA). Scaffold
specimens were compressed in steps of Dl = 1 mm
(0.2 mm/s) and the displacement held for 20 s before
applying the subsequent compression step. From the initial
force peak of each step (DF), the equivalent elastic modulus
(E) was calculated as E = DFlo/ADl, where A is the cross-
sectional area and lo the nominal height of the specimen.
MSCs isolation and culture
Fresh bone marrow (BM) samples were obtained from the
iliac crest or the vertebral body of the donors during sur-
gery after informed consent and approval by the ethics
committee of canton Lucerne. MSCs were isolated from
BM of ten patients (average age: 35 ± 14 years). The BM
aspirates were diluted twofold in 3.8% sodium citrate and
1 9 phosphate buffered saline (PBS) and filtered through a
100 lm cell strainer (Falcon, BD Bioscience). Mononu-
clear cells were separated by Ficoll gradient centrifugation
(density 1.077 g/mL; GE Healthcare) in a Leucosep tube
(Greiner) at 800g for 20 min, washed with PBS, centri-
fuged again at 250g for 10 min, re-suspended in 10 mL
PBS and counted using trypan blue dye in a single use
Neubauer chamber (C-Chip Typ Neubauer, Zeiss). Cells
were placed in a T150 tissue culture flask (TPP) in Non-
hematopoietic (NH) stem cell media (Miltenyi) at 37C in
a humid atmosphere containing 5% CO2. After 2 days,
non-adherent cells were discarded, whereas adherent cells
were cultured in DMEM/F12 ? GlutaMAX, supplemented
with 10% foetal bovine serum (FBS), (100 units/mL)
penicillin/(100 mg/mL) streptomycin, 2.5 ng/mL ampho-
tericin B (all GIBCO) and 5 ng/mL recombinant basic
Fibroblast Growth Factor (bFGF, Peprotech) with medium
changed 3 times a week. At 80% confluence, cells were
harvested by dissociation with 0.05% trypsin, used for
seeding scaffolds, or expanded to another passage, or
cryopreserved at -150C in a medium containing 45%
DMEM/F12, 45% FBS and 10% dimethyl sulfoxide
(DMSO). Cells used in this project were expanded for no
more than 4 passages in culture.
NP Cells isolation and culture
Human NP cells were isolated from patients with disc
trauma who underwent full or partial discectomy (Table 1)
after approval of local ethics committee. NP fragments
were digested with 0.05% collagenase (Sigma-Aldrich),
10% FBS, (100 units/mL) penicillin/(100 mg/mL) strep-
tomycin in DMEM/F12 ? GlutaMAX for 5 h at 37C.
After incubation, cell suspension was filtered through a
100 lm cell strainer and centrifuged for 5 min, and the
pellet was washed with PBS. NP cells were expanded in
culture for 20 days (two passages) as a monolayer in
identical conditions as the ones used for expanding MSCs.
Scaffold constructs
The four sponge-shaped medical devices were made of
collagen derived from different species, gelatin and chito-
san. Collagen matrixes were composed of: lyophilized
collagen extracted from horse flexor tendon (Biopad) or
collagen from porcine corium (inner dermis layer) (ABE
collagen, Beese) and gelatin––a partially hydrolyzed col-
lagen (Spongostan, Ferrosan). The last matrix, chitosan
(Beese medical), was produced by de-acetylation of chitin.
From these materials, cubes with 3 mm side length were
cut and used as a support for cellular growth. The cell
suspension was pipetted on the construct and completely
absorbed by it. MSCs construct were kept at RT for 30 min
to allow cells to anchor to the matrix, before the careful
addition of media to the 6-well plate. The resulting MSC-
matrix constructs were used in further experiments. A pilot
experiment comparing different cell densities revealed an
optimal cell suspension concentration of 4 9 106 cells/mL,
which was used for all experiments.
MSC chondrogenic differentiation
To induce chondrogenesis, MSC constructs were main-
tained for 35 days in chondrogenic medium and compared
to control. Chondrogenic medium consisted of DMEM/
Table 1 Demographic details of annulus fibrosus and nucleus pul-
posus donors
Sample Sex Donor’s age
(years)
Thompson
grading scale
Type of operation
1 F 44 IV Trauma Discectomy
L2/3
2 M 29 III Trauma Discectomy
L1/2
3 M 17 IV Trauma Discectomy
L1/2
Average age = 30 ± 12 years old, (L lumbar vertebrae)
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F12 ? GlutaMAX, supplemented with 2.5% FBS, 40 ng/mL
dexamethasone (Applichem), 50 lg/mL ascorbate-2-phos-
phate (Sigma), 50 lg/mL L-proline (Sigma), 100 U/mL pen-
icillin–100 mg/mL streptomycin, 2.5 ng/mL amphotericin B,
1X insulin (10 lg/mL), transferrin (5.5 lg/mL), selenium
(0.67 ng/mL), X supplement (ITS, Gibco), and 10 ng/mL
transforming growth factor-b1 (TGF-b1) (Peprotech). Con-
trols were maintained in DMEM/F12 ? GlutaMAX, sup-
plemented with penicillin–streptomycin, amphotericin B,
FBS and ITS. The media was replaced three times per week.
RNA isolation, cDNA synthesis and real time PCR
Total RNA isolation from MSC constructs was performed
at days 7 and 35 and RNA stored at -80C as follows;
constructs were homogenized using a Dispomix device
(Axonlab). RNA was isolated from control NP fragments
(n = 3; Thompson grading scale II) by hammering of the
dry ice frozen samples and further using Aurum Total Mini
Kit (Bio Rad), adding 2 ll polyacryl carrier to the lysis
buffer and following the manufacturer’s instructions. Five
hundred nanograms of total RNA were used for synthesis
of cDNA (iScript cDNA Synthesis Kit, BioRad), which
was diluted 1:10 with ultrapure water and the resulting
cDNA template (5 ll) was mixed with the PCR reaction
solution (IQ SYBR Green Supermix, BioRad) containing
0.25 lM specific primers as described in Table 2. Specific
products (GAPDH, aggrecan, CD45, CD73, CD90, CD105,
collagen type I, collagen type II, FOXF1, Keratin 19,
PAX1 and osteopontin) were amplified by a quantitative
PCR system (CFX96
TM
Real Time System, BioRad). qPCR
was carried out in triplicates in a final volume of 25 ll in
96-well plates (Bio Rad), with the following settings:
denaturation at 95C for 3 min (1 cycle), at 95C for 15 s,
at 64C for 20 s and at 72C for 20 s (40 amplification
cycles), followed by a melting curve analysis. The results
were normalized to the expression of GAPDH.
Immunohistological analysis
Immunohistochemical analysis was used to detect aggre-
can, collagen type I and type II accumulations. Constructs
were harvested at 35 days of culture in chondrogenic
medium, embedded in Neg-50 compound for 30 min, fro-
zen at -80C and subsequently sectioned at 20 lm using a
cryostat (CM 1850, Leica).
Endogenous peroxidase was quenched by 3% H2O2 in
PBS at room temperature for 10 min, and washed with
PBS. Before incubation with anti-collagen type II antibody,
sections were pre-treated for 40 min with 2,500 U/mL
hyaluronidase (Sigma-Aldrich) in PBS at 37C, while
sections for immunodetection with anti-aggrecan antibody
were pre-treated with chondroitinase ABC (0.25 U/mL,
Sigma-Aldrich) in 0.1 M Tris 0.03 M acetate buffer pH 6.5
for 3 h at 37C. Non-specific background was blocked with
PBS containing 1 mg/mL BSA, 10% FBS and 0.1% Triton
(Applichem) for 30 min followed by overnight incubation
at 4C with monoclonal mouse antibodies against collagen
type I (1:20; M-38, Development Studies Hybridoma
Bank), collagen type II (1:20; II-II6B3, Development
Studies Hybridoma Bank) and aggrecan (1:10,000;
AHP0022, Biosource) in blocking solution. After washing
with PBS, sections were incubated with a secondary bio-
tinylated goat anti-mouse antibody (1:200; B0529, Sigma),
and then with streptavidin-horseradish peroxidase (1:200;
S2438, Sigma) for 45 min at room temperature. Aggrecan,
and collagen types I and II were visualized by reac-
tion with 0.075% solution of 3-amino-9-ethylcarbazole
(AEC, Applichem) in 0.01% H2O2. Sections were mounted
with 70% glycerol (Applichem) and examined by light
microscopy.
Histological detection of sulfated glycosaminoglycan
(GAG) accumulation was carried out by alcian blue
staining. Sections were stained overnight with 0.4% alcian
Table 2 Human marker genes used in quantitative RT-PCR
Gene Primer nucleotide sequence (50–30) Product
size (bp)
GAPDH F-TGGACTCCACGACGTACTCA 102
R-GGAAGCTTGTCATCAATGGAA
Aggrecan F-AGGCTATGAGCAGTGTGAACG 125
R-GCACGCCATAGGTCCTGA
CD45 F-CAGTTTCCCCATTGACAACC 120
R-CAGAGGCATTAAGGTAGGCATC
CD73 F-CCAGTCCACTGGAGAGTTCC 111
R-CGACACTTGGTGCAAAGAAC
CD90 F-AGGACGAGGGCACCTACAC 107
R-GCCCTCACACTTGACCAGTT
CD105 F-GCTTGTTGCGCATTTGAA 95
R-GGCTCGATGGTGTTGGAG
Collagen
type I
F-CCTCCTGGCTCTCCTGGT 106
R-AGGGAGACCGTTGAGTCCAT
Collagen
Type II
F-GAAGTGCTGGTGCTCGTG 125
R-GGCCTCTCCTTGCTCACC
FOXF1 F-CAGCCTCTCCACGCACTC 122
R-CCTTTCGGTCACACATGCT
PAX1 F-GCAATGACCTTCAAGCATCC 91
R-GGCAGTCCGTGTAAGCTACTG
Keratin 19 F-GCCACTACTACACGACCATCC 126
R-CAAACTTGGTTCGGAAGTCAT
Osteopontin F-GAGGGCTTGGTTGTCAGC 129
R-CAATTCTCATGGTAGTGAGTTTTCC
F Forward, R reverse
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blue (Fluka) dissolved in 0.01% H2SO4 and 0.5 M guani-
dine hydrochloride (Fluka). Next, sections were washed for
30 min in 40% DMSO and 0.05 M MgCl2. Finally, sec-
tions were mounted with 70% glycerol and examined by
light microscopy.
Glycosaminoglycans (GAG) accumulation and DNA
assays
Proteoglycan accumulation was quantified with alcian blue
binding assay after 6 h digestion of three constructs per
sample at 60C with 125 lg/mL papain (Sigma-Aldrich) in
5 mM L-cysteine-HCl (Sigma-Aldrich), 5 mM Na-citrate,
150 mM NaCl, 5 mM EDTA (all AppliChem). GAG
accumulation was determined by binding to alcian blue
(Fluka), absorption was measured at 595 nm and quantified
against chondroitin sulfate (Sigma-Aldrich) reference
standards [33].
Total double stranded DNA was measured for each
sample after papain digestion, as previously described. The
amount of DNA was determined using SYBR green
(Invitrogen) fluorescent assay (absorption measured at
535 nm), quantified by referring to calf thymus DNA
(Sigma-Aldrich) standards. All test groups were analyzed
in triplicates.
Statistical analysis
Data were collected from triplicate samples and expressed
as the mean ± SD. Non-parametric Mann–Whitney–Wil-
coxon U test for dependent variables was used to compare
gene expression, DNA quantification and GAG accumu-
lation, because ANOVA would assume normal distribution
of the data, which cannot be guaranteed in this data set. For
all tests, p \ 0.05 was considered significant. Data analysis
was performed with SPSS 14.0 for Windows (SPSS Inc.).
Results
Matrix and cell characterization and cell-construct
behavior
The stiffness of dry scaffolds was tested and represented as
average modulus (Fig. 1a). Chitosan was up to twofold
stiffer than equine collagen and gelatin. Equine collagen
was the softest matrix, with an average modulus 20% that
of chitosan. All matrixes possessed the typical response of
a viscoelastic material (Fig. 1b): first, an immediate force
peak is followed by relaxation; second, the force increment
with each displacement step increased as the material was
compressed. The chitosan matrix needed to be compressed
over 10% before it showed any response and it also
possessed the peculiar characteristic to permanently
deform easily, although its stiffness was higher than other
matrixes. The other matrixes were characterized by a softer
structure, but they rebounded elastically when the force
was released, although the gelatin was also fragile.
Scanning electron micrographs showed different poros-
ity and structure among matrixes (Fig. 1c). Equine and
porcine collagen matrixes were characterized by a thick
plot of fibers, more densely packed in the equine collagen.
On the other hand, gelatin and chitosan presented with
more homogeneous and ordered structures where gelatin
was to be noted for the largest size of pores. Notably, in the
chitosan matrix the pore structure assumed a tubular
‘‘honeycomb’’ shape, whereas in the other matrixes the
structures were more reminiscent of a net.
MSCs grown in monolayer displayed the typical
fibroblast-like morphology and MSCs phenotype was
assessed by positive gene expression of the characteristic
antigens CD73, CD90 and CD105 [34], and absence of
expression of the leukocyte common marker CD45 (data
not shown).
Depending on the time in culture, constructs undergoing
chondrogenic differentiation conditions reduced their size
compared to the initial size (Fig. 2). Porcine collagen
constructs shrank drastically after 3 days, equine collagen
constructs after 7 days. Gelatin constructs showed moder-
ate condensation during chondrogenesis, while chitosan
constructs remained almost unaltered and size throughout
the whole period of differentiation.
Quantification of gene expression levels of MSCs
To follow MSC differentiation, the gene expression of disc
and bone markers were analyzed by real-time PCR on the
7th and 35th days in chondrogenic culture and normalized
to the respective gene expression of MSCs in chitosan
constructs at day 7 (Fig. 3). After 7 days in culture, porcine
collagen constructs already had an up-regulated expression
of chondrogenic markers. Compared to chitosan, MSCs
seeded in the porcine collagen matrix expressed higher
RNA levels of collagen type II (*1,100-fold, p \ 0.01),
aggrecan (300-fold, p \ 0.01) and collagen type I
(*threefold p \ 0.01). Also compared to chitosan con-
structs, the osteogenic marker osteopontin was significantly
up-regulated in alginate beads (50-fold, p \ 0.05) and
porcine collagen constructs (37-fold, p \ 0.01), but not in
equine collagen and gelatin samples. After 35 days in
chondrogenic media, MSCs’ expression of collagen type II
was significantly higher in MSCs in gelatin (30,000-fold,
p \ 0.01), equine collagen (60,000-fold, p \ 0.01), por-
cine collagen and alginate beads (18,000-fold, p \ 0.05)
and chitosan (1,500-fold, p \ 0.05) compared to chitosan
constructs at day 7 (Fig. 3a). Similar pattern but not level
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of expression was observed for aggrecan (Fig. 3b). MSCs
in gelatin and both collagen matrixes reached approxi-
mately *7,000-fold increase (p \ 0.01) compared to
*4,000-fold increase in alginate (p \ 0.05), while in
chitosan aggrecan gene expression increased only *250-
fold compared to day 7 (p \ 0.05). The highest MSC levels
of expression of collagen type II and aggrecan were
achieved in equine collagen and porcine collagen scaffolds,
respectively. Expression of collagen type I was signifi-
cantly up-regulated in all collagen-derived matrixes by
approximately fourfold (p \ 0.01); while it remained low
in alginate beads and chitosan constructs (Fig. 3c). Gene
expression of osteopontin (Fig. 3d) was highest in alginate
beads (1,500-fold, p \ 0.05), followed by porcine collagen
(90-fold, p \ 0.01), and equal in chitosan, equine collagen
and gelatin constructs (35-fold, p \ 0.01).
We also grouped MSCs data by donor’s age, creating
two groups––with average age of 25 and 55 years. Gene
expression analysis revealed that cells in the older group
significantly up-regulated the expression of collagen type I,
while collagen type II, aggrecan and osteopontin levels
were comparable between the two groups (data not shown).
Protein accumulation and localization
Histological and immunohistochemical analysis showed
that, depending on the scaffold used, the specific extracel-
lular matrix components which characterize chondrogenic
differentiation were produced to different extent (Fig. 4).
Alcian blue staining was particularly intensive in collagen
and gelatin constructs, indicating extracellular deposition of
proteoglycans. Compared to these constructs, staining in
Fig. 1 Stiffness measurements of dry matrixes (a) and representation
of results obtained for chitosan, which possessed the typical response
of a viscoelastic material (b) Scanning electron microphotographs of
equine collagen, gelatin, porcine collagen and chitosan matrixes
(c) (Scale bar is 100 lm in the upper row and 10 lm in the lower
row)
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alginate beads and in the chitosan matrix was considerably
lower. Immunostaining of the alginate constructs showed
that collagen type I accumulation was higher compared to
collagen type II and aggrecan (almost undetectable). On the
contrary, in the collagen and gelatin matrixes, immuno-
staining demonstrated a specific pattern of protein deposi-
tion: collagen type I formed a thin outer layer surrounding
the constructs (with oriented collagen fibrils somewhat
Fig. 2 Images of scaffolds at
day 0 and constructs at days 3, 7
and 35 during chondrogenic
differentiation. (Entire scale bar
is 3 mm)
Fig. 3 Gene expression of collagen type II (a), aggrecan (b),
collagen type I (c) and osteopontin (d) by MSCs in chitosan, equine
collagen, gelatin, porcine collagen constructs and alginate beads after
7 and 35 days of chondrogenic culture. Data are normalized to MSCs
expression in chitosan constructs at day 7. (Gene expression was
normalized to GAPDH, and represented as a mean ± SD, *p \ 0.05
and **p \ 0.01 compared to MSCs expression in chitosan constructs
at day 7)
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resembling AF), while the inner part was positive for col-
lagen type II and to lower extent for aggrecan. In compar-
ison, in the chitosan matrix, collagen type I production was
also spread across the section, while collagen type II and
aggrecan were deposed in much lower amounts.
Cell number and GAG accumulation in MSC constructs
To estimate cell number, total dsDNA content was mea-
sured for all MSC constructs after 35 days in chondrogenic
culture (Fig. 5a). Compared to alginate beads and chitosan,
DNA amount was significantly higher in equine and por-
cine collagen constructs (*20-fold, p \ 0.05) and in gel-
atin constructs (*tenfold, p \ 0.05). Non significant DNA
increase was measured for equine collagen constructs in
control media culture.
After 35 days, different scaffolds showed variable GAG
accumulation (Fig. 5b). The overall accumulation of GAG
was measured and normalized per construct. GAG showed a
significant increase (p \ 0.05) in every construct compared to
chitosan: porcine collagen 120-fold, equine collagen 60-fold,
gelatin 30-fold and alginate beads tenfold. GAG accumulation
with control medium in the equine collagen construct
remained at the level of the chitosan group. When GAG
accumulation was normalized to DNA, the highest ratio
between accumulated GAG and total DNA was in alginate
beads (Fig. 5c), this ratio being twofold more than in gelatin,
equine and porcine collagen constructs, and approximately
tenfold more than chitosan constructs (p \ 0.05).
Chondrogenic markers expression ratio in MSC
compared to NP cells
To analyze and compare the potential of MSCs to undergo
NP-like chondrogenesis in different scaffolds, we calcu-
lated the ratio of collagen type II/aggrecan (COL2/ACAN),
compared these to NP cells in the respective scaffolds as
well as to ex vivo NP tissue fragments (Fig. 6). The COL2/
ACAN ratio was significantly higher in alginate, equine
collagen, gelatin (p \ 0.05) and chitosan (p \ 0.01) MSCs
construct compared to NP cells, except in the porcine
collagen matrix. In this particular scaffold, the ratios were
comparable to NP cells because MSCs expressed higher
levels of aggrecan compared to MSCs in other supports.
NP fragments were characterized by COL2/ACAN gene
expression ratio of approximately 1:1.
Gene expression of nucleus pulposus markers
by differentiated MSCs
To improve the discrimination between cartilage-like and
NP-like differentiation of MSCs in different scaffolds after
5 weeks in chondrogenic medium, we tested the expression
Fig. 4 Microphotographs of alginate beads, equine collagen,
gelatin, porcine collagen and chitosan sections of constructs
stained after 35 days of chondrogenic culture (On the right as a
control, sections of equine collagen-construct in control media).
The deposition of proteoglycan-rich extracellular matrix was
defined by alcian blue staining (upper row). Immunohistochemical
analysis of collagen type I (second row), collagen type II (third
row) and aggrecan (bottom row), where positive staining is
indicated by the presence of red-brown staining. (Entire scale bar
is 200 lm)
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of genes recently associated with NP phenotype [35, 36],
namely KER19, PAX1 and FOXF1 (Fig. 7). Gene
expression levels were normalized to MSCs in respective
scaffolds and represented as fold increase. Chitosan is not
shown because both MSC constructs with this scaffold
were not expressing the analyzed genes. Independent of the
scaffold used, gene expression levels of PAX1 and FOXF1
were significantly and substantially higher in NP cells
when compared to MSCs (p \ 0.01). The expression of
KRT19 by MSCs and NP cells was not significantly dif-
ferent in alginate, but in contrast the expression of PAX1
and FOXF1 in NP cells was over 1000-fold and approxi-
mately 100-fold, respectively higher compared to MSCs
expression. The average NP:MSCs expression ratio for
PAX1 and FOXF1 of the collagen and gelatin constructs
was approximately 550- and 10-fold, respectively. In all
scaffolds, but alginate and porcine collagen scaffold,
mRNA expression of KRT19 was higher in NP cells
compared to MSCs (p \ 0.05). Interestingly, in the porcine
collagen construct the gene expression of PAX1 and
FOXF1 by MSCs was the closest to NP cells, related to the
other scaffolds.
Fig. 5 DNA quantification in
alginate beads, equine collagen,
gelatin, porcine collagen and
chitosan constructs after
35 days of chondrogenic
culture, and in control media
(equine collagen) (a), GAG
accumulation per bead (b), and
GAG/DNA ratio in the same
samples (c) (Values represent
the triplicate mean ± standard
deviation; *p \ 0.05 compared
to chitosan construct values)
Fig. 6 Comparison between gene expression levels of MSCs and NP
cells. RNA from NP fragments is represented as reference. Results are
reported as ratio of collagen type II to aggrecan RNA expression.
(Relative expression normalized to GAPDH, and data are represented
as a mean ± SD, *p \ 0.05 and **p \ 0.01)
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Discussion
In this study, we compared the effects of four different
scaffolds to that of alginate for 3D cultures of MSCs
derived from bone marrow extracts and differentiated in
vitro to generate disc-like cells. Alginate is broadly used in
in vitro experiments and provides an easy to control 3D cell
culture environment. Previous studies have demonstrated
differentiation of MSCs in alginate to NP-like cells [25, 26]
but direct comparison with medically approved, although
for different applications, materials was not done before.
Since a range of these medical devices are made of bio-
logical extracellular matrix molecules, we hypothesized
that they may support equally to or better than alginate
chondrogenic differentiation. Indeed, our results clearly
showed that scaffolds are a key component for MSCs
undergoing differentiation characteristic for the NP of IVD
[2], and we demonstrated that collagen and gelatin are
more effective than alginate in enhancing the expression of
relevant matrix genes such as collagen types I and II,
aggrecan and accumulation of proteoglycans. On the con-
trary, as a scaffold, chitosan was characterized by a low
gene expression and production of extracellular matrix, as
well as low cell survival. The data indicates that MSCs can
be stimulated by culture conditions to express collagen
type II/aggrecan in a ratio similar to that of NP cells cul-
tured in vitro, however gene expression analyses of
recently identified NP markers [35], demonstrated that
MSCs compared to NP cells express these markers in a
different pattern.
The use of 3D cultures for tissue engineering is imper-
ative, because only in such cultures chondrogenic differ-
entiation of MSCs is possible. In vitro pre-differentiation of
MSCs, or introduction of cell and scaffold together to the
site of the IVD repair, could be a key step for the future
implantation of MSCs, because already committed cells
would be able to re-build immediately the needed extra-
cellular matrix. Several materials have been studied in the
form of hydrogels or porous scaffolds. Alginate gel is one
of the most used supports for MSC chondrogenesis, but it
was shown that in vivo implantation of the gel without cells
was inhibiting the spontaneous repair of the tissue [37] and
that cell-alginate constructs can induce in some cases
severe immunological responses [38]. Further, alginate is
mechanically unstable and therefore inappropriate for
implant in vivo [39]. Also synthetic polymers, like poly-
glycolic acid (PGA), poly0-L-lactic acid (PLA) and
copolymer poly-lactic-co-glycolic acid (PLGA) were
shown to promote some inflammation in vivo [40]. On the
contrary, collagen is not only a natural molecule but also
the main component of the extracellular matrix of IVD.
Also natural materials, when not prepared properly, might
be unsuitable as supports for in vivo transplantation
because of fast degradation rates, possible transmission of
pathogens and viruses from the derivation source of the
material, and undesired breakdown products [29]. We
might be able to overcome some of these problems by
using bio-materials already approved for human use, such
as wound healing or in surgery, which will have the
advantages of being supplied sterile, validated to be non-
Fig. 7 Gene expression
analysis of keratin 19 (KRT19),
paired box 1 (PAX1) and
forkhead box F1 (FOXF1) by
MSCs and NP cells after
35 days of culture. Results are
represented for each matrix:
alginate (a), equine collagen
(b), gelatin (c) and porcine
collagen (d) and normalized to
MSCs expression. Chitosan data
are absent because of lack of
expression of these genes.
(Relative expression normalized
to GAPDH, and data are
represented as a mean ± SD,
*p \ 0.05 and **p \ 0.01)
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toxic and biocompatible, thus simplifying lengthy and
expensive procedures for translation of research into clinic.
All materials used in this study were sponge-like, safe and
easy to handle, permitting precise control over size and
shape. Scanning electron microscopy imaging showed that
the collagen scaffolds used contain highly interconnected
pores with a rougher fibrous surface and the gelatin matrix
had a smoother structure with more homogeneous pore size
and more open space distribution. The chitosan matrix had
the most ordered structure with ‘‘honeycomb’’ tubular
geometrical, combined with highest stiffness of all tested
materials but unfortunately was the most inept of all
materials with regard to MSC differentiation into NP-like
phenotype.
By the end of 5 weeks, collagen constructs were char-
acterized by a strong shrinkage exerted by the MSCs, as
shown by dramatic levels of condensation. The estimated
shrinkage was more than a ninefold reduction, to reach
only fraction of the initial volume. Collagen matrixes are
softer than chitosan and this property allowed MSCs to
condense the constructs in a process analogous to the first
step of in vivo cartilage development [41]. Possibly, high
modulus materials might be a better option for bone
development, since bone often develops after a primary
cartilage matrix already exists. This hypothesis is con-
firmed by alginate beads, which in supporting MSC
chondrogenesis, performed in between chitosan and soft
collagens and gelatin. In alginate beads, cells can com-
municate with each other within the soft gel, however they
cannot pull and condense the whole bead, so histological
analysis shows microsites of extracellular matrix deposi-
tion, without the additional effect of the condensation and
the formation of a more homogenous tissue. Histological
and immunohistochemical assays showed the deposition of
extracellular matrix characterized by COL1, COL2, and
ACAN and alcian blue staining-sulfated proteoglycan.
Remarkably, extracellular matrix production from the
MSCs was not evenly distributed throughout the collagen
constructs. The inner part of the constructs showed accu-
mulation of large amounts of COL2, proteoglycans and
ACAN, while the outer perimeter was covered in parallel
layers of COL1. These results may suggest that MSCs
reacted diversely to different oxygen gradient established
across the construct. GAG accumulation per bead was
higher in the collagen and gelatin constructs compared to
alginate beads, but lower when normalized to DNA. This
has to be viewed with caution as the result is caused by the
low long-term cell survival which characterizes alginate
beads cultures.
In agreement with the histological data, MSCs in colla-
gen constructs expressed higher levels of the IVD and
cartilage markers COL1, COL2 and ACAN compared to
alginate constructs. In contrast, the undesired bone marker
OPN was significantly lower in gelatin and collagen as
compared to alginate constructs, confirming lower level, or
lack of osteogenesis. Altogether, these results suggest that
the deposition of extracellular matrix in collagen constructs
was similar to that in NP. In particular, in porcine collagen
constructs, MSCs expression ratio for COL2/ACAN was
the closest to that of NP cells seeded in the same scaffold.
Despite these encouraging results, one of the major limi-
tations we faced was that the MSC gene expression levels of
the recently discovered NP markers PAX1 and FOXF1 [35]
were approximately 500- and 10-fold lower, respectively,
than NP cells seeded in the same supports, therefore far
from ideal. Further studies, which will show what are the
specific underlying biological functions of these genes in
the IVD tissue, will enable better differentiation protocols.
At day 35, the cell number (based on DNA quantity)
was significantly higher in gelatin, equine and porcine
collagen constructs compared to alginate and chitosan
constructs. Some of the performance difference between
constructs might be also explained by the uneven number
of cells attached to each scaffolds. Low percentage (2.5%)
FBS was added to media to improve cell viability, since
without it MSCs in the control group would not have
survived the duration of the experiment.
Interestingly, when grouping donors by age, it became
evident that MSCs chondrogenic potential could not be
based only on donor’s age, a potentially important obser-
vation for future autologous cell therapies.
In conclusion, after 5 weeks of differentiation, we
demonstrated that collagen and gelatin scaffolds are readily
available and suitable matrixes for chondrogenic differen-
tiation of MSCs in vitro, in comparison to alginate bead
cultures and chitosan constructs. The possibility of use in
future clinical IVD applications cannot be excluded and
may take fewer resources than some alternative options.
However, the expression of recently identified NP markers
by MSCs was significantly lower compared to NP cells
seeded in the same matrixes, which calls for additional in
vitro and in vivo investigations on the biology of MSC
differentiation and IVD development.
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